Biological membrane material adopting cell transplantation as carrier

A technology of cell transplantation and biofilm, applied in the direction of unknown raw materials, prostheses, medical preparations with non-active ingredients, etc., can solve the problems of greater repellency and achieve the effect of improving affinity

Inactive Publication Date: 2020-11-24
ANHUI HUIEN BIOTECH
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Aiming at the deficiencies of the prior art, the purpose of the present disclosure is to provide a biofilm material using cell transplantation as a carrier, which solves the problem of the inconsistency between cells of different human bodies or different tissues and organs in the process of transplantation of embryonic stem cells in the prior art. big exclusionary problem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biological membrane material adopting cell transplantation as carrier

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] 1. Raw material preparation:

[0038] 1) Full-term normal delivery of human fetal amniotic membrane,

[0039] 2) 1% concentration of ammonia water,

[0040] 3) Antibiotics (using penicillin, clarithromycin, clindamycin),

[0041] 4) balanced salt solution (0.9% NACL solution),

[0042] 5) 0.2% trypsin solution,

[0043] 6) 5% concentration of PLLA solution,

[0044] 11) DMEM culture fluid containing 5% serum,

[0045] 12) Co60 radioactive source;

[0046] 2. Select the placenta within 30 minutes after delivery of the first child of healthy puerpera without infectious diseases and systemic diseases;

[0047] 3. Bluntly separate the amniotic membrane from the placenta under sterile conditions;

[0048] 4. Place the amniotic membrane in balanced salt solution for injection containing penicillin (800,000 u / 500ml), clarithromycin (1 million u / 500ml) and clindamycin (1 million u / 500ml), shake and wash for 3 Once, 5 minutes each time, wash off the blood and mucus, take...

Embodiment 2

[0061] 1. Raw material preparation:

[0062] 1) Full-term normal delivery of human fetal amniotic membrane,

[0063] 2) 2% ammonia water,

[0064]3) Antibiotics (using penicillin, clarithromycin, clindamycin),

[0065] 4) balanced salt solution (0.9% NACL solution),

[0066] 5) 0.25% trypsin solution,

[0067] 6) 8% concentration of PLLA solution,

[0068] 13) DMEM culture fluid containing 10% serum,

[0069] 14) Co60 radioactive source;

[0070] 2. Select the placenta from 30 minutes to 60 minutes after delivery of the first child of healthy puerpera without infectious diseases and systemic diseases;

[0071] 3. Bluntly separate the amniotic membrane from the placenta under sterile conditions;

[0072] 4. Place the amniotic membrane in balanced salt solution for injection containing penicillin (800,000 u / 500ml), clarithromycin (1 million u / 500ml) and clindamycin (1 million u / 500ml), shake and wash for 3 Once, 5 minutes each time, wash off the blood stains and mucus, t...

Embodiment 3

[0085] 1. Raw material preparation:

[0086] 1) Full-term normal delivery of human fetal amniotic membrane,

[0087] 2) 5% concentration of ammonia water,

[0088] 3) Antibiotics (using penicillin, clarithromycin, clindamycin),

[0089] 4) balanced salt solution (0.9% NACL solution),

[0090] 5) 0.3% trypsin solution,

[0091] 6) 10% concentration of PLLA solution,

[0092] 15) DMEM culture fluid containing 15% serum,

[0093] 16) Co60 radioactive source;

[0094] 2. Select the placenta from 60-90 minutes after delivery of the first child of healthy puerpera without infectious diseases and systemic diseases;

[0095] 3. Bluntly separate the amniotic membrane from the placenta under sterile conditions;

[0096] 4. Place the amniotic membrane in balanced salt solution for injection containing penicillin (800,000 u / 500ml), clarithromycin (1 million u / 500ml) and clindamycin (1 million u / 500ml), shake and wash for 3 Once, 5 minutes each time, wash off the blood stains and m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a biological membrane material adopting cell transplantation as a carrier, and particularly relates to the field of medical transplantation. A layer of biological membrane structure is inoculated on the surface of an embryonic stem cell, so that the embryonic stem cell cannot be recognized by an immune cell in a recipient cell, and the transplanting success rate is increased; and by culturing and extracting the amniotic membrane of a human fetus subjected to full-term normal delivery, a biological membrane which can be inoculated on the embryonic stem cell is prepared,and the affinity of the embryonic stem cell is improved.

Description

technical field [0001] The disclosure belongs to the field of medical transplantation, in particular to a biofilm material using cell transplantation as a carrier. Background technique [0002] With the continuous development of science and technology, cell transplantation technology is developing faster and faster. Among them, the most common one is human stem cell transplantation. In the field of stem cell transplantation, embryonic stem cells are the most widely used. Embryonic stem cells are totipotent and can be used to induce differentiation For other cells and tissues, any disease that causes the loss of normal cells can be treated by transplanting specific tissue cells differentiated from embryonic stem cells, such as using nerve cells to treat neurodegenerative diseases (Parkinson's syndrome, Huntington's disease, Alzheimer's disease, Alzheimer's disease, etc.) Haimer's disease, etc.), use hematopoietic stem cells to rebuild blood building function, use pancreatic i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61L27/36A61L27/38A61K35/545A61K47/46
CPCA61K35/545A61K47/46A61L27/3604A61L27/3687A61L27/3691A61L27/3834A61L2300/30A61L2300/412
Inventor 熊志军刘文董欣
Owner ANHUI HUIEN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap